OR WAIT null SECS
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Alcon is asking the FDA to approve a new drug application for its travoprost 0.004% plus timolol 0.5% fixed combination (TTFC) for the reduction of IOP in the treatment of glaucoma.
Related Content: